Equities research analysts forecast that Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) will report earnings of ($0.03) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Osmotica Pharmaceuticals’ earnings. Osmotica Pharmaceuticals posted earnings of ($4.99) per share during the same quarter last year, which suggests a positive year over year growth rate of 99.4%. The company is expected to report its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Osmotica Pharmaceuticals will report full-year earnings of ($0.25) per share for the current fiscal year. For the next financial year, analysts expect that the business will report earnings of ($0.12) per share, with EPS estimates ranging from ($0.18) to ($0.06). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Osmotica Pharmaceuticals.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.06. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%. The company had revenue of $57.53 million for the quarter, compared to the consensus estimate of $57.90 million.
OSMT has been the topic of a number of research analyst reports. Jefferies Financial Group set a $10.00 price target on Osmotica Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 12th. Barclays assumed coverage on Osmotica Pharmaceuticals in a report on Tuesday, June 11th. They set an “overweight” rating and a $11.00 target price on the stock. Zacks Investment Research downgraded Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Wells Fargo & Co reiterated a “buy” rating on shares of Osmotica Pharmaceuticals in a report on Friday, August 9th. Finally, ValuEngine upgraded Osmotica Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Osmotica Pharmaceuticals has a consensus rating of “Buy” and an average target price of $13.00.
Several hedge funds have recently bought and sold shares of the business. Sofinnova Investments Inc. grew its holdings in shares of Osmotica Pharmaceuticals by 107.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 525,198 shares of the company’s stock worth $1,996,000 after acquiring an additional 272,109 shares during the period. BlackRock Inc. purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth approximately $3,682,000. Millennium Management LLC purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth approximately $2,568,000. Northern Trust Corp grew its holdings in shares of Osmotica Pharmaceuticals by 5.6% during the 2nd quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock worth $378,000 after acquiring an additional 5,230 shares during the period. Finally, Geode Capital Management LLC purchased a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth approximately $668,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.
NASDAQ:OSMT traded down $0.03 during mid-day trading on Wednesday, reaching $2.97. 34,900 shares of the company’s stock traded hands, compared to its average volume of 110,835. Osmotica Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $9.90. The firm has a market capitalization of $154.56 million and a price-to-earnings ratio of -5.82. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.78 and a quick ratio of 1.49. The company has a 50 day moving average price of $3.39 and a 200-day moving average price of $4.38.
Osmotica Pharmaceuticals Company Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: Stochastic Momentum Index (SMI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.